Analyst
Raymond James
Analyst
Canaccord Genuity
Equibles does not estimate personal net worth.
Gary Nachman is recorded as Analyst at Raymond James and Analyst at Canaccord Genuity. Gary Nachman has spoken on 7 earnings calls and 3 other investor events across 9 companies, most recently for Entera Bio Ltd. on August 12, 2026. Those appearances were for Adma Biologics, Inc. (ADMA), Entera Bio Ltd. (ENTX), Scholar Rock Holding Corp (SRRK), Tonix Pharmaceuticals Holding Corp. (TNXP), Ani Pharmaceuticals Inc (ANIP) and 4 other companies. The companies whose calls Gary Nachman spoke on are classified in the Healthcare sector.
“Miranda's been with Interra on the board since 2018 and is CEO since 2022, and it's been a labor of love. I think it's fair to characterize that to progress EB613 for osteoporosis through development.”
“And we're very excited to have David Halal, CEO of Scalarock, with us to discuss all the recent developments at the company. David's been CEO since April of last year and has been chairman of the board since 2017.”
“Seth co-founded Tonics back in 2007, so it's been quite a journey for you as you've built a pretty robust portfolio across several therapeutic areas, CNS, infectious disease, immunology, and rare disease.”
“So, what portion of cortropin volume was from gouty arthritis flares in 2Q versus 1Q? If you could quantify that, it would be helpful. And maybe where do you see that going by the end of the year?”
“Adam, on the increasing demand for Ascentive, you previously talked about growth of 2 to 4 percent month-on-month. Do you expect it to continue at that rate or could it possibly be even better than that? but it sounded like it accelerated nicely in June.”
Raymond James
Analyst
Source not stated
Canaccord Genuity
Analyst
Source not stated
ADMA
Biotechnology · Healthcare
ENTX
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
ABBV
Drug Manufacturers - General · Healthcare
